Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.
Int J Mol Sci
; 22(14)2021 Jul 16.
Article
in English
| MEDLINE | ID: covidwho-1389404
ABSTRACT
In the past few years, Bruton's tyrosine Kinase (Btk) has emerged as new target in medicinal chemistry. Since approval of ibrutinib in 2013 for treatment of different hematological cancers (as leukemias and lymphomas), two other irreversible Btk inhibitors have been launched on the market. In the attempt to overcome irreversible Btk inhibitor limitations, reversible compounds have been developed and are currently under evaluation. In recent years, many Btk inhibitors have been patented and reported in the literature. In this review, we summarized the (ir)reversible Btk inhibitors recently developed and studied clinical trials and preclinical investigations for malignancies, chronic inflammation conditions and SARS-CoV-2 infection, covering advances in the field of medicinal chemistry. Furthermore, the nanoformulations studied to increase ibrutinib bioavailability are reported.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Protein Kinase Inhibitors
/
Agammaglobulinaemia Tyrosine Kinase
Type of study:
Experimental Studies
/
Prognostic study
Limits:
Humans
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
IJMS22147641
Similar
MEDLINE
...
LILACS
LIS